NASDAQ$BTAI
Bioxcel Therapeutics Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported positive results from SERENITY trials, strengthened balance sheet, and advanced clinical programs.
BioXcel Therapeutics reported positive results from its SERENITY trials for BXCL501, plans to submit an NDA to the FDA in Q1 2021, and strengthened its balance sheet through a follow-on offering. The company is also advancing its TRANQUILITY and RELEASE trials and exploring alternative indications for BXCL501. Additionally, the immuno-oncology program is progressing with the Phase 2 efficacy trial of BXCL701 and KEYTRUDA®.
- SERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; NDA submission to FDA planned for Q1 2021.
- Initiating the third dose cohort, 90 mcg, of the TRANQUILITY trial in elderly dementia patients.
- Initiated a separate efficacy cohort in the Phase 2 trial of BXCL701 in combination with pembrolizumab to include patients with castrate-resistant prostate cancer.
- Strengthened balance sheet through follow-on offering raising approximately $200 million in gross proceeds.
Headline financials
Revenue & EPS history
Bioxcel Therapeutics · Revenue · Quarterly
$0
Revenue by segment
Bioxcel Therapeutics · $206K total across 1 segment · Q1 2026
- IGALMI$206K—100.0%
Forward guidance
The company is focused on submitting an NDA for BXCL501 to the FDA in the first quarter of 2021 and advancing its clinical programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2020
-3.1%
Avg return
Earnings day
-5.5%
Avg return
5 days after
-9.4%
Avg return
30 days after
30%
10 / 33 earnings
Positive
+38.7%
Q3 2022
Best reaction
-44.1%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -5.6% | -8.7% | — | |
| Q1 2026 | -5.8% | -9.9% | -5.0% | |
| Q3 2025 | -16.0% | -9.4% | -0.5% | |
| Q2 2025 | +6.5% | -14.4% | -47.0% | |
| Q1 2025 | +0.0% | -4.8% | +6.8% | |
| Q4 2024 | +6.0% | -11.9% | -14.2% | |
| Q3 2024 | -8.2% | -2.6% | -33.4% | |
| Q2 2024 | -1.0% | -20.5% | -35.9% | |
| Q1 2024 | -1.4% | +0.5% | -33.3% | |
| Q4 2023 | -1.0% | -7.6% | -3.8% | |
| Q3 2023 | -20.1% | -25.0% | -41.2% | |
| Q2 2023 | -44.1% | -41.5% | -54.3% | |
| Q1 2023 | +17.7% | +18.6% | -9.6% | |
| Q4 2022 | -27.2% | -28.3% | -39.1% | |
| Q3 2022 | +38.7% | +41.1% | +49.2% | |
| Q2 2022 | -9.7% | -5.9% | -9.4% | |
| Q1 2022 | -10.6% | -6.5% | -6.7% | |
| Q4 2021 | -8.3% | -20.3% | -9.4% | |
| Q3 2021 | -2.4% | -19.7% | -35.5% | |
| Q2 2021 | +2.2% | -1.6% | +19.3% | |
| Q1 2021 | +8.1% | +3.1% | +27.2% | |
| Q4 2020 | +3.8% | +2.0% | -20.7% | |
| Q3 2020 | -4.1% | -8.6% | -23.8% | |
| Q2 2020 | -4.7% | -6.3% | +0.5% | |
| Q1 2020 | +0.1% | +9.6% | +6.7% | |
| Q4 2019 | -3.9% | -39.8% | -35.5% | |
| Q3 2019 | +12.4% | +40.6% | +48.3% | |
| Q2 2019 | -15.1% | -7.5% | +2.6% | |
| Q1 2019 | +12.8% | +9.4% | +5.3% | |
| Q4 2018 | -6.6% | +12.3% | +23.1% | |
| Q3 2018 | -7.9% | -12.6% | -21.8% | |
| Q2 2018 | -1.8% | -9.6% | -8.5% | |
| Q1 2018 | -4.9% | +3.6% | -1.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro